MAVENCLAD 10 mg tablets

DRUG4 trials

Sponsors

María Luisa Martínez Ginés, Helse Bergen HF, Varsinais-Suomen hyvinvointialue, Aristotle University Of Thessaloniki

Conditions

Multiple SclerosisMultiple sclerosis

Phase 3

Randomized Autologous heMatopoietic stem cell transplantation versus alemtuzumab, cladribine or ocrelizumab for patients with relapsing remitting Multiple Sclerosis (RAM-MS)

Active, not recruitingCTIS2024-510630-40-00

Helse Bergen HFMultiple sclerosis

Start: 2018-02-12Target: 100Updated: 2024-06-12

Phase 4

A phase IV, unicentric, open label clinical trial to evaluate the default mode network in multiple sclerosis patients on Cladribine treatment.

Not yet recruitingCTIS2023-504577-21-00

María Luisa Martínez GinésMultiple Sclerosis

Target: 20Updated: 2023-06-26

Effect of cladribine treatment on microglial activation in the CNS

Active, not recruitingCTIS2024-519921-39-00

Varsinais-Suomen hyvinvointialueMultiple Sclerosis

Start: 2019-08-16Target: 15Updated: 2025-02-12

Effects of CLADribine tablets on the Immune Synapse, in Relapsing Multiple Sclerosis (RMS) patients_CLADIS.

Not yet recruitingCTIS2025-521910-24-00

Aristotle University Of ThessalonikiMultiple Sclerosis

Target: 30Updated: 2026-04-17